Latest Breaking News On - ஆர்ஃபந் மருந்து பதவி நிலை - Page 1 : comparemela.com

AIM ImmunoTech Inc. AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food and Drug Administration on December 17, 2020 granted Orphan Drug Designation status to AIM’s drug Ampligen (rintatolimod) for the treatment of pancreatic cancer.

United statesThomask equelsImmunotech incCrescendo communicationsErasmus university medical centerPancreatic cancer action networkEarly access programDrug administration onEuropean medicines agencyOrphan drug designation statusDrug administrationOrphan drug designationPancreatic cancer actionPrivate securities litigation reform actஒன்றுபட்டது மாநிலங்களில்பிறை தகவல்தொடர்புகள்